"Substandard drugs are as much a driver of antimicrobial resistance as irrational use." Examine this in light of the proposed amendment to the NDCT Rules, 2019.
New · District CollectorCan you hold the district for 72 hours?Floods, a heatwave, an outbreak, a grievance queue. Take the decisions, see the consequences.Play →In this answer
Antimicrobial resistance (AMR) is when microbes survive the drugs meant to kill them. Policy has long blamed irrational use. The Health Ministry's draft G.S.R. 983 (E) would bring antimicrobials under the "New Drug" definition of the NDCT Rules, 2019. In doing so, it recognises that poor-quality drugs also feed resistance [1].
Irrational use: the established driver
- Over-the-counter sale, self-medication and needless prescriptions expose microbes to drugs they don't need to face.
- CDSCO has placed 24 high-end antimicrobials under Schedule H1 to curb misuse [6].
Substandard drugs: an equal but hidden driver
- Scale: WHO found a 10.5% failure rate for medical products in low- and middle-income countries, and antibiotics are among the most reported [2].
- Mechanism: a weak drug gives a sub-therapeutic dose. Resistant strains survive, and doctors must move to costlier second-line drugs [3].
- Indian evidence: a national survey of 47,012 samples found 1,850 NSQ (not of standard quality) but only 13 spurious [4]. CDSCO labs declared 1,014 of 16,548 samples NSQ in FY 2025–26 [5]. So the main problem is poor batches from licensed units, not fakes.
- The two drivers compound each other: even correct prescribing fails if the pill is under-strength.
What the amendment does
- Central Licensing Authority permission becomes a precondition for the state manufacturing licence [1].
- BA/BE and stability studies must be scrutinised. Until now these were often skipped [1].
Limits of the approach
- Licensing-stage only: it checks the product's design, not every batch made later.
- Precedent: FDCs (fixed-dose combinations) were already "new drugs". Yet states licensed many of them without DCGI approval, which led to the Kokate Committee review and mass bans [7].
- Capacity and cost: CDSCO will face a heavier approval load, and small manufacturers will bear compliance costs.
- Reactive recalls: patients often take NSQ batches before they are detected.
On balance, the statement largely holds: substandard drugs and irrational use are twin drivers of AMR that reinforce each other. The draft rightly targets the quality pathway. It needs support from a better-staffed CDSCO, risk-based market sampling of antimicrobials and a check that each state licence matches a central permission. Stewardship under the National Action Plan on AMR must continue alongside it. Together these would protect the right to health under Article 21 and advance SDG 3.
Sources
- 1MoHFW: "Union Health Ministry Proposes Amendment to New Drugs and Clinical Trials Rules, 2019 to Bring Antimicrobials under Central Regulatory Oversight" (PIB; the exact release page could not be reached, so this links the PIB home page)draft G.S.R. 983 (E), the "New Drug" definition, CLA permission before the SLA licence, BA/BE and stability scrutiny
- 2WHO: 1 in 10 medical products in developing countries is substandard or falsified (2017)10.5% failure rate; antibiotics among the most reported
- 3WHO: Antimicrobial resistance and primary health care (brief)sub-therapeutic dosing selects for resistance; shift to second-line drugs
- 4PIB: Health Ministry undertakes largest ever drug survey in the world for determining the quality of drugs1,850 NSQ and 13 spurious out of 47,012 samples
- 5MoHFW: Initiatives & Achievements 2025 (PIB)1,014 of 16,548 samples NSQ in FY 2025–26
- 6PIB: Nafithromycin, Country's First Indigenous Antibiotic24 high-end antimicrobials under Schedule H1 to prevent misuse
- 7PIB: Prohibition and restriction of manufacture, sale and distribution of FDCs (the exact release page could not be reached, so this links the PIB home page)states licensed FDCs without DCGI approval; Kokate Committee; bans